Vivanza Biosciences Ltd

AI
Vivanza Biosci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Vivanza Biosciences Ltd

₹ 1.80 2.86%
24 Aug - close price
vivanzabiosciences.com BSE: 530057
About

Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]

Key Points

Business Overview:[1]
VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products

Website BSE
  • Market Cap ₹ 7.20 Cr.
  • Current Price ₹ 1.80
  • High / Low ₹ 2.72 / 1.52
  • Stock P/E 15.6
  • Book Value ₹ 1.09
  • Dividend Yield 0.00 %
  • ROCE 6.11 %
  • ROE 9.38 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Debtor days have improved from 196 to 39.0 days.

Cons

  • Promoter holding is low: 20.0%
  • Company has a low return on equity of 2.11% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -27.8%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
9.23 7.62 6.56 4.42 2.44 3.00 1.50 0.48 8.94 55.36 45.25 6.36 9.29
8.64 7.30 6.27 4.56 2.08 2.89 1.37 1.44 8.79 54.75 45.04 6.59 9.36
Operating Profit 0.59 0.32 0.29 -0.14 0.36 0.11 0.13 -0.96 0.15 0.61 0.21 -0.23 -0.07
OPM % 6.39% 4.20% 4.42% -3.17% 14.75% 3.67% 8.67% -200.00% 1.68% 1.10% 0.46% -3.62% -0.75%
0.01 0.05 0.02 -0.03 0.00 0.00 0.01 0.05 0.02 0.01 0.08 0.01 0.37
Interest 0.11 0.11 0.10 0.09 0.09 0.09 0.09 0.08 0.08 0.05 0.09 0.07 0.11
Depreciation 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01
Profit before tax 0.49 0.26 0.21 -0.27 0.27 0.02 0.05 -0.99 0.09 0.57 0.20 -0.30 0.18
Tax % 0.00% 0.00% 0.00% 55.56% 0.00% 0.00% 0.00% 1.01% 0.00% 0.00% 0.00% 50.00% 22.22%
0.49 0.26 0.21 -0.41 0.27 0.02 0.04 -1.00 0.09 0.56 0.20 -0.45 0.15
EPS in Rs 0.12 0.06 0.05 -0.10 0.07 0.00 0.01 -0.25 0.02 0.14 0.05 -0.11 0.04
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
0 3 6 3 10 10 10 18 28 7 116 116
0 4 6 3 10 10 10 17 27 8 115 116
Operating Profit -0 -0 1 -0 -0 0 -0 1 1 -0 1 1
OPM % -9% 9% -0.8% -3.6% 0.9% -0.6% 3.8% 3.9% -4.9% 0.6% 0.5%
0 0 0 0 1 1 1 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Profit before tax -0 -0 0 -0 -0 0 0 1 1 -1 1 1
Tax % 0% 0% 13% 0% 0% 42% 0% 17% 21% 2% 27%
-0 -0 0 -0 -0 0 0 1 1 -1 0 0
EPS in Rs -0.32 -0.08 0.05 -0.11 -0.05 0.02 0.08 0.15 0.14 -0.17 0.10 0.12
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 64%
3 Years: 87%
TTM: 735%
Compounded Profit Growth
10 Years: 24%
5 Years: 37%
3 Years: -13%
TTM: 154%
Stock Price CAGR
10 Years: -13%
5 Years: -31%
3 Years: -45%
1 Year: -14%
Return on Equity
10 Years: 2%
5 Years: 6%
3 Years: 2%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.19 4 4 4 4 4 4 4 4 4 4
Reserves -0 -0 -0 -1 -1 -1 -1 0 1 -0 0
0 1 1 1 0 0 6 8 5 9 10
0 3 5 6 9 5 7 10 10 4 8
Total Liabilities 1 7 10 11 12 8 16 22 20 16 22
0 2 2 2 2 2 2 2 2 2 2
CWIP 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0
1 5 8 9 10 6 13 20 17 14 20
Total Assets 1 7 10 11 12 8 16 22 20 16 22

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 -2 -0 1 3 -3 2 -1 2 -2 -3
0 2 0 0 0 -0 0 0 -0 -0 -0
0 0 -1 -1 -3 3 -2 1 -2 2 3
Net Cash Flow 0 0 -1 -0 0 -0 -0 0 0 -0 -0
Free Cash Flow 0 -2 -0 1 3 -3 2 -1 2 -3 -3
CFO/OP 0% 668% -15% -4,300% -876% -3,367% -4,117% -124% 203% 692% -328%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 267 287 782 250 231 275 256 151 398 39
Inventory Days 215 150 309 38 26 92 55 28 121 11
Days Payable 304 319 878 319 154 207 211 116 140 23
Cash Conversion Cycle 178 118 213 -32 103 160 99 64 379 27
Working Capital Days 332 237 469 109 104 103 50 44 154 7
ROCE % -10% 13% -0% 6% 17% 12% 11% 10% -3% 6%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Foreign Exchange Earnings (Exports)
Rs. in Lakhs ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of Permanent Employees
count ・Standalone data
Subsidiary Revenue (Vivanza Lifesciences Pvt Ltd)
Rs. in Lakhs ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
47.29% 44.90% 43.24% 40.05% 39.86% 20.02% 20.02% 20.02% 20.02% 20.02% 20.02% 20.02%
52.70% 55.10% 56.75% 59.95% 60.13% 79.98% 79.98% 79.98% 79.98% 79.98% 79.98% 79.98%
No. of Shareholders 5,0395,9376,99216,94116,70120,63520,83320,45820,17019,82219,46119,254

Documents

Announcements

Annual reports